Details:
Advanz Pharma secures exclusive rights from Alvotech to commercialize AVT05, a biosimilar candidate to Simponi and Simponi Aria (golimumab), AVT16, a proposed biosimilar to Entyvio (vedolizumab), and three additional early-stage, undisclosed biosimilar candidates in Europe.
Lead Product(s): Golimumab
Therapeutic Area: Immunology Product Name: AVT05
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Advanz Pharma
Deal Size: $343.4 million Upfront Cash: $60.1 million
Deal Type: Partnership May 24, 2023
Details:
The new agreement adds another biosimilar candidate to the partnership between Alvotech and Fuji, first announced in 2018, bringing the total number of proposed biosimilar products that the companies are partnering on to six.
Lead Product(s): AVT16
Therapeutic Area: Immunology Product Name: AVT16
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Fuji Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 23, 2022